CN113769169A - Anticoagulation cell adhesion-promoting biological valve material and preparation method thereof - Google Patents
Anticoagulation cell adhesion-promoting biological valve material and preparation method thereof Download PDFInfo
- Publication number
- CN113769169A CN113769169A CN202111231079.5A CN202111231079A CN113769169A CN 113769169 A CN113769169 A CN 113769169A CN 202111231079 A CN202111231079 A CN 202111231079A CN 113769169 A CN113769169 A CN 113769169A
- Authority
- CN
- China
- Prior art keywords
- acid
- biological valve
- solution
- valve material
- glutaraldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title claims abstract description 47
- 230000010100 anticoagulation Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 238000004132 cross linking Methods 0.000 claims abstract description 25
- 210000003516 pericardium Anatomy 0.000 claims abstract description 20
- 230000021164 cell adhesion Effects 0.000 claims abstract description 19
- 230000004048 modification Effects 0.000 claims abstract description 18
- 238000012986 modification Methods 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 4
- 210000004379 membrane Anatomy 0.000 claims description 29
- 239000012528 membrane Substances 0.000 claims description 29
- 238000002791 soaking Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 15
- -1 O- (benzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate Chemical compound 0.000 claims description 14
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 12
- 229920000669 heparin Polymers 0.000 claims description 12
- 229960002897 heparin Drugs 0.000 claims description 12
- 108010039918 Polylysine Proteins 0.000 claims description 11
- 229920000656 polylysine Polymers 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 7
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- ACVAAFHNDGTZLL-UHFFFAOYSA-N 5-(2,5-dioxopyrrol-1-yl)pentanoic acid Chemical compound OC(=O)CCCCN1C(=O)C=CC1=O ACVAAFHNDGTZLL-UHFFFAOYSA-N 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- IYGAMTQMILRCCI-UHFFFAOYSA-N 3-aminopropane-1-thiol Chemical compound NCCCS IYGAMTQMILRCCI-UHFFFAOYSA-N 0.000 claims description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 229920002873 Polyethylenimine Polymers 0.000 claims description 3
- 229960003638 dopamine Drugs 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 claims description 2
- ULZJAHZPCLFGHQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-(2,5-dioxopyrrol-1-yl)pentanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCN1C(=O)C=CC1=O ULZJAHZPCLFGHQ-UHFFFAOYSA-N 0.000 claims description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims description 2
- ODVRLSOMTXGTMX-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrole-2,5-dione Chemical compound NCCN1C(=O)C=CC1=O ODVRLSOMTXGTMX-UHFFFAOYSA-N 0.000 claims description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 claims description 2
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 claims description 2
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 claims description 2
- IUTPJBLLJJNPAJ-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)CCN1C(=O)C=CC1=O IUTPJBLLJJNPAJ-UHFFFAOYSA-N 0.000 claims description 2
- NCPQROHLJFARLL-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)butanoic acid Chemical compound OC(=O)CCCN1C(=O)C=CC1=O NCPQROHLJFARLL-UHFFFAOYSA-N 0.000 claims description 2
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 239000004114 Ammonium polyphosphate Substances 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 229920001276 ammonium polyphosphate Polymers 0.000 claims description 2
- 235000019826 ammonium polyphosphate Nutrition 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 2
- 229940099500 cystamine Drugs 0.000 claims description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- 229960003151 mercaptamine Drugs 0.000 claims description 2
- 229960001639 penicillamine Drugs 0.000 claims description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 2
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229940005642 polystyrene sulfonic acid Drugs 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 229960002317 succinimide Drugs 0.000 claims description 2
- 230000009471 action Effects 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000003146 anticoagulant agent Substances 0.000 description 10
- 230000010355 oscillation Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 208000018578 heart valve disease Diseases 0.000 description 4
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- MDNSLPICAWKNAG-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C(=O)C=CC1=O MDNSLPICAWKNAG-UHFFFAOYSA-N 0.000 description 1
- PPRBGMXQDAMDAB-UHFFFAOYSA-N 2-(prop-2-enoylamino)propanoic acid Chemical compound OC(=O)C(C)NC(=O)C=C PPRBGMXQDAMDAB-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000000635 valve cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
The invention discloses an anticoagulation and cell adhesion promotion biological valve material and a preparation method thereof. The preparation method comprises the following steps: and performing glutaraldehyde crosslinking on the biological valve material, and performing modification treatment on the biological valve material by using a modification solution A and/or a modification solution B before and/or after the glutaraldehyde crosslinking. The invention combines one or more modified materials on the pericardium through the chemical bond action and the charge interaction, can ensure that the artificial biological valve has the performances of long-acting anticoagulation and cell adhesion promotion, and can also improve the mechanical property and the structural stability of the artificial biological valve.
Description
Technical Field
The invention belongs to the technical field of preparation of medical materials and medical instruments, and particularly relates to an anticoagulation cell adhesion-promoting biological valve material and a preparation method thereof.
Background
In recent years, cardiovascular diseases have become the biggest threat to human life health, wherein valvular heart diseases have become common heart diseases in our country. With the aging of the population becoming more serious, patients with valvular heart disease are increasing year by year. Heart valvular diseases are mainly manifested as stenosis or insufficiency. Once a heart valve is narrowed or incompletely closed, it can obstruct the normal flow of blood, severely increase the heart burden, cause damage to the heart function, and lead to heart failure. For severe heart valve disease, surgical valve replacement and transcatheter minimally invasive valve replacement are currently the most common treatment modalities. Bioprosthetic valves are the main components of traditional surgical open-chest valve replacement and emerging transcatheter valve replacement, and are the most value-added components. The artificial biological valve used clinically at present is mainly prepared by acellular and glutaraldehyde crosslinking treatment of pig pericardium or bovine pericardium. However, the biological valve prosthesis prepared by glutaraldehyde crosslinking has high toxicity, is difficult to realize cell adhesion, is easy to cause adverse clinical events such as thrombus and the like, and even worse, can also reduce the service life of the biological valve prosthesis and cause serious threat to the life health of patients.
The aldehyde group remained after the glutaraldehyde crosslinking is an important reason causing great toxicity of the artificial heart valve, and although part of free aldehyde group can be blocked by lysine, arginine or polycation and the like, the adhesion performance of the artificial biological valve cell is not obviously improved. In addition, grafting anticoagulant drugs by physical adsorption or chemical coupling and the like is a common method for improving the anticoagulant performance of the artificial biological valve, but the two strategies are respectively limited by short effective period and unsatisfactory anticoagulant effect. Therefore, effectively blocking free aldehyde groups on the glutaraldehyde cross-linked artificial biological valve and realizing long-acting anticoagulation of the artificial biological valve is expected to prolong the service life of the artificial biological valve, thereby improving the life of patients.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides an anticoagulation and cell adhesion promotion biological valve material and a preparation method thereof, aiming at endowing the anticoagulation and cell adhesion promotion capability to the artificial biological valve so as to prolong the service life of the artificial biological valve.
In order to achieve the purpose, the technical scheme adopted by the invention for solving the technical problems is as follows:
a preparation method of an anticoagulant cell adhesion-promoting biological valve material comprises the following steps: and (3) carrying out glutaraldehyde crosslinking on the biological valve material, and modifying the biological valve material by using a modified solution A or a modified solution B before and/or after the glutaraldehyde crosslinking.
The method specifically comprises the following steps:
soaking the biological valve material in the modified solution A or the modified solution B, and then performing glutaraldehyde crosslinking;
or the biological valve material is firstly cross-linked by glutaraldehyde and then soaked in the modified solution A or the modified solution B;
or soaking the biological valve material in the modified solution A or the modified solution B, then carrying out glutaraldehyde crosslinking, and finally soaking the crosslinked biological valve material in the modified solution A or the modified solution B.
Further, the process of modifying the biological valve material by adopting the modified solution A or the modified solution B comprises the following steps:
soaking a biological valve material or a biological membrane material crosslinked by glutaraldehyde into a modified solution A or a modified solution B with the pH value of 0.5-12, and soaking for 2-96 h at 4-40 ℃ in a shaking manner.
Further, the mass concentration of the modification solution A or the modification solution B is 0.001-20%.
Further, the modified solution A is cysteine, penicillamine, cystamine, lysine, arginine, histidine, cysteamine, mercaptopropylamine and amino thiophenol, at least one of dopamine, 1-ethyl- (3-dimethylaminopropyl) carbodiimide, N-hydroxysuccinimide, diisopropylcarbodiimide, 4-dimethylaminopyridine, 2- (7-azabenzotriazole) -N, N, N ', N' -tetramethyluronium hexafluorophosphate, 4- (4, 6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride, 1-hydroxybenzotriazole and O- (benzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate.
Further, the modifying solution B is polyethyleneimine, maleimide undecyl succinimide ester, lysine, arginine, polylysine, 3-maleimido propionic acid hydroxysuccinimide ester, chitosan, ammonium polyphosphate, polyhexamethylene dimethylammonium bromide, polyhydroxyethyl cellulose ether quaternary ammonium salt, guar gum, gum arabic, choline, polyimidazolium salt, hyaluronic acid, 4-maleimido butyric acid, 3-maleimido propionic acid, polyacrylic acid, polysulfonic acid, polyacrylic acid and sodium salt thereof, KPEPVC peptide, polymethacrylic acid and sodium salt thereof, polyvinylsulfonic acid and salt thereof, polystyrenesulfonic acid and salt thereof, (2-acrylamido-2-methylpropanesulfonic acid) polymer, 6-maleimido caproic acid, 6- (maleimido) caproic acid succinimide ester, poly (2-acrylamido) propionic acid, poly (2-maleimido) succinimide ester, poly (2-maleimido) caproic acid, poly (2-maleimido) copolymer, poly (2-maleimido) propionic acid, poly (2-ethylenephosphonic acid), poly (2-maleimido) succinimide ester, poly (2-ethylenephosphonic acid), poly (2-maleimido) amide), poly (2-ethylenephosphonic acid), poly (2-maleimido) amide), poly (2-bis (2-maleimido-one, poly (2-ethylenephosphonic acid), poly (2-maleimide), poly (ethylenephosphonic acid), poly (2-maleimide), poly (ethylenephosphonic acid), poly (, At least one of maleimidoacetic acid succinimidyl ester, polyarginine, N- (2-aminoethyl) maleimide, 5-maleimidovaleric acid, polyacrylamide, heparin, 5-maleimidovaleric acid NHS, sodium alginate, 4-maleimidobutyric acid-N-succinimidyl ester, and CRGD peptide.
Further, the preparation process of the modified solution A or the modified solution B comprises the following steps:
and stirring and dissolving the weighed modified solution A or modified solution B at 4-60 ℃, and adjusting the pH value to 0.5-12.
Further, the pH value of the modified solution A or the modified solution B is 5-8.
Further, the pH values of the modifying solution a and the modifying solution B were both 7.4.
Further, the pH values of the modifying solution a and the modifying solution B were both 5.5.
Further, the modification solution A comprises mercaptopropylamine, 1-ethyl- (3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide in a molar weight ratio of 1:1.5: 1.5.
Modification solution B: comprises a mixed solution, 5-maleimidovaleric acid, 1-ethyl- (3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide in a mass ratio of 2:0.1:0.12: 0.12; the mixed solution comprises polylysine and heparin, the mass concentration of the polylysine is 0.3%, the mass concentration of the heparin is 0.2%, and the volume ratio of the polylysine to the heparin is 1:1.
Further, the process of glutaraldehyde crosslinking is:
and soaking the biological valve material into a glutaraldehyde solution with the pH value of 0.5-12 and the temperature of 4-40 ℃, and oscillating and soaking for 2-96 hours.
Further, the biological valve material is acellular pericardium.
Further, decellularized pericardium includes, but is not limited to, porcine pericardium and bovine pericardium.
An anticoagulant cell adhesion-promoting biological valve material is prepared by the method.
The invention has the beneficial effects that:
1. the invention realizes the long-acting anticoagulation and cell adhesion promotion performance of the artificial biological valve by soaking the acellular pericardium in a modified solution and then crosslinking glutaraldehyde, or soaking the glutaraldehyde crosslinked pericardium in the modified solution, or soaking the acellular pericardium in the modified solution and crosslinking glutaraldehyde, and then further soaking the acellular pericardium in the modified solution, and combining one or more modified materials on the pericardium through the chemical bond action and charge interaction.
2. According to the invention, the acellular pericardium is soaked in the modified solution, so that the modified material is fully combined with the pericardium and is further crosslinked with glutaraldehyde, thereby increasing crosslinking sites, enabling the modified material to be stably combined with the pericardium, improving the functionality of the artificial biological valve, and improving the mechanical property and structural stability of the artificial biological valve.
3. Compared with the artificial biological valve which is cross-linked by simple glutaraldehyde, the artificial biological valve provided by the invention has the advantages of obviously improved anticoagulation performance and capability of promoting cell adhesion.
Drawings
FIG. 1 is a scanning electron microscope (A) of the adhesion of platelets and a scanning electron microscope (B) of the adhesion of platelets of a pure glutaraldehyde cross-linked membrane of a biological valve material prepared in example 2;
FIG. 2 is a fluorescent microscope picture (A) of endothelial cell adhesion and a fluorescent microscope picture (B) of pure glutaraldehyde cross-linked membrane cell adhesion of the biological valve material prepared in example 2.
Detailed Description
The following description of the embodiments of the present invention is provided to facilitate the understanding of the present invention by those skilled in the art, but it should be understood that the present invention is not limited to the scope of the embodiments, and it will be apparent to those skilled in the art that various changes may be made without departing from the spirit and scope of the invention as defined and defined in the appended claims, and all matters produced by the invention using the inventive concept are protected.
Example 1
A preparation method of an anticoagulant cell adhesion-promoting biological valve material comprises the following specific processes:
modification solution A: 0.5 percent of dopamine by mass concentration and 7.4 of pH value;
modification solution B: mixed solution of polyethyleneimine and heparin with mass concentration of 0.3% and 0.2%, respectively, and pH value of 7.4.
Soaking the acellular bovine pericardium in the modified solution A at 4 ℃ for 24 hours under a slight oscillation condition; then, cleaning the membrane with clear water, soaking the membrane in the modified solution B for 24 hours at 4 ℃ under a slight oscillation condition; taking out the membrane, washing the membrane with clear water, then further treating the membrane with glutaraldehyde, wherein the concentration of the glutaraldehyde is 1 percent, the pH value of the glutaraldehyde is 7.4, and crosslinking the membrane for 48 hours at room temperature under the oscillation condition; and taking out the glutaraldehyde crosslinked membrane, washing the membrane with clear water, and further treating the membrane with a modified solution B for 24 hours to obtain the biological valve material with anticoagulation and cell adhesion promotion functions.
The tensile breaking stress of the artificial biological valve material prepared by the embodiment is slightly better than that of a membrane prepared by glutaraldehyde crosslinking. Platelet adhesion experiments show that the artificial biological valve material prepared by the embodiment has remarkably improved anti-platelet adhesion capability, a large amount of cell adhesion can be observed in the artificial biological valve prepared by the embodiment, and the cell adhesion phenomenon is not observed basically in the membrane prepared by glutaraldehyde crosslinking.
Example 2
A preparation method of an anticoagulant cell adhesion-promoting biological valve material comprises the following specific processes:
modification solution A: mercaptopropylamine, 1-ethyl- (3-dimethylaminopropyl) carbodiimide, and N-hydroxysuccinimide in a molar ratio of 1:1.5:1.5 were dissolved in distilled water at a pH of 5.5.
Modification solution B: comprises a mixed solution, 5-maleimidovaleric acid, 1-ethyl- (3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide in a mass ratio of 2:0.1:0.12: 0.12; the mixed solution comprises polylysine and heparin, the mass concentration of the polylysine is 0.3%, the mass concentration of the heparin is 0.2%, and the volume ratio of the polylysine to the heparin is 1:1. Then, the above components were dissolved in distilled water to have a pH of 5.5.
Soaking the acellular bovine pericardium in the modified solution A at 25 ℃ for 24 hours under the oscillation condition; then, cleaning the membrane with clear water, soaking the membrane in the modified solution B for 24 hours at 25 ℃ under an oscillation condition; after soaking, taking out the membrane, washing with clear water, further treating with glutaraldehyde, wherein the concentration of the glutaraldehyde is 1%, the pH value is 7.4, and crosslinking for 48 hours at 25 ℃ under an oscillation condition; and taking out the crosslinked membrane, washing the membrane with clear water, and further treating the membrane with a modified solution B for 24 hours to obtain the biological valve material with anticoagulation and cell adhesion promotion functions.
The tensile breaking stress of the artificial biological valve material prepared by the embodiment is equivalent to that of a membrane prepared by crosslinking glutaraldehyde. Platelet adhesion experiments show that the artificial biological valve material prepared by the embodiment has remarkably improved anti-platelet adhesion capability, a large amount of cell adhesion can be observed in the artificial biological valve prepared by the embodiment, and the cell adhesion phenomenon is not observed basically in the membrane prepared by glutaraldehyde crosslinking.
Example 3
A preparation method of an anticoagulant cell adhesion-promoting biological valve material comprises the following specific processes:
modification solution B: comprises a mixed solution, 5-maleimidovaleric acid, 1-ethyl- (3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide in a mass ratio of 3:0.1:0.12: 0.12; the mixed solution comprises polylysine and heparin, the mass concentration of the polylysine is 0.3%, the mass concentration of the heparin is 0.2%, and the volume ratio of the polylysine to the heparin is 1:1. Then, the above components were dissolved in distilled water to have a pH of 5.5.
Soaking the acellular bovine pericardium in the modified solution B at 25 ℃ for 24 hours under the oscillation condition; after soaking, taking out the membrane, washing with clear water, further treating with glutaraldehyde, wherein the concentration of the glutaraldehyde is 1%, the pH value is 7.4, and crosslinking for 48 hours at 25 ℃ under an oscillation condition; and taking out the crosslinked membrane, washing the membrane with clear water, and further treating the membrane with a modified solution B for 24 hours to obtain the biological valve material with anticoagulation and cell adhesion promotion functions.
The tensile breaking stress of the artificial biological valve material prepared by the embodiment is slightly better than that of a membrane prepared by glutaraldehyde crosslinking. Platelet adhesion experiments show that the artificial biological valve material prepared by the embodiment has remarkably improved anti-platelet adhesion capability, a large amount of cell adhesion can be observed in the artificial biological valve prepared by the embodiment, and the cell adhesion phenomenon is not observed basically in the membrane prepared by glutaraldehyde crosslinking.
Claims (9)
1. A preparation method of an anticoagulation and cell adhesion promotion biological valve material is characterized in that a biological valve material is subjected to glutaraldehyde crosslinking, and a modification solution A and/or a modification solution B is/are adopted to carry out modification treatment on the biological valve material before and/or after the glutaraldehyde crosslinking.
2. The preparation method according to claim 1, wherein the modification treatment of the biological valve material by using the modification solution A or the modification solution B comprises the following steps:
soaking a biological valve material or a biological membrane material crosslinked by glutaraldehyde into a modified solution A or a modified solution B with the pH value of 0.5-12, and soaking for 2-96 h at 4-40 ℃ in a shaking manner.
3. The method according to claim 1 or 2, wherein the modifying solution A or B has a mass concentration of 0.001 to 20%.
4. The method according to claim 3, wherein the modified solution A is cysteine, penicillamine, cystamine, lysine, arginine, histidine, cysteamine, mercaptopropylamine, aminothiophenol, at least one of dopamine, 1-ethyl- (3-dimethylaminopropyl) carbodiimide, N-hydroxysuccinimide, diisopropylcarbodiimide, 4-dimethylaminopyridine, 2- (7-azabenzotriazole) -N, N, N ', N' -tetramethyluronium hexafluorophosphate, 4- (4, 6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride, 1-hydroxybenzotriazole and O- (benzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate.
5. The method according to claim 3, wherein the modifying solution B is polyethyleneimine, maleimide-undecenoic acid succinimide ester, lysine, arginine, polylysine, 3-maleimidopropionic acid hydroxysuccinimide ester, chitosan, ammonium polyphosphate, polyhexamethylene bromide, polyhydroxyethyl cellulose ether quaternary ammonium salt, guar gum, gum arabic, choline, polyimidazolium salt, hyaluronic acid, 4-maleimidobutyric acid, 3-maleimidopropionic acid, polyacrylic acid, polysulfonic acid, polyacrylic acid and sodium salt thereof, KPVC EPpeptide, polymethacrylic acid and sodium salt thereof, polyvinylsulfonic acid and salt thereof, polystyrenesulfonic acid and salt thereof, (2-acrylamido-2-methylpropanesulfonic acid) polymer, 6-maleimidocaproic acid, 6- (maleimido) caproic acid succinimide ester, and, At least one of maleimidoacetic acid succinimidyl ester, polyarginine, N- (2-aminoethyl) maleimide, 5-maleimidovaleric acid, polyacrylamide, heparin, 5-maleimidovaleric acid NHS, sodium alginate, 4-maleimidobutyric acid-N-succinimidyl ester, and CRGD peptide.
6. The method according to claim 3, wherein the modifying solution A or the modifying solution B is prepared by:
and stirring and dissolving the weighed modified solution A or modified solution B at 4-60 ℃, and adjusting the pH value to 0.5-12.
7. The method according to claim 1, wherein the glutaraldehyde crosslinking is carried out by:
and soaking the biological valve material into a glutaraldehyde solution with the pH value of 0.5-12 and the temperature of 4-40 ℃, and oscillating and soaking for 2-96 hours.
8. The method of claim 1 or 2, wherein the biological valve material is a decellularized porcine pericardium or bovine pericardium.
9. An anticoagulation cell adhesion-promoting biological valve material, which is prepared by the method of any one of claims 1-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111231079.5A CN113769169A (en) | 2021-10-22 | 2021-10-22 | Anticoagulation cell adhesion-promoting biological valve material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111231079.5A CN113769169A (en) | 2021-10-22 | 2021-10-22 | Anticoagulation cell adhesion-promoting biological valve material and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113769169A true CN113769169A (en) | 2021-12-10 |
Family
ID=78873379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111231079.5A Pending CN113769169A (en) | 2021-10-22 | 2021-10-22 | Anticoagulation cell adhesion-promoting biological valve material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113769169A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115645618A (en) * | 2021-11-17 | 2023-01-31 | 四川大学 | Method for preparing biological valve material by co-crosslinking and double-bond crosslinking and biological valve material |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2237229A1 (en) * | 1998-05-08 | 1999-11-08 | Derek Boughner | An improved bioprosthetic heart valve |
| CN107412865A (en) * | 2016-10-27 | 2017-12-01 | 浙江保尔曼生物科技有限公司 | The decellularization kidney biological support and preparation method with anticoagulant functions of high intensity |
| CN107441556A (en) * | 2017-07-05 | 2017-12-08 | 北京大清生物技术股份有限公司 | A kind of tissue mending material of polyaminoacid end-blocking and preparation method thereof |
| CN108404219A (en) * | 2018-02-11 | 2018-08-17 | 华中科技大学 | A kind of small-caliber artificial blood vessel and preparation method thereof based on freezing casting technology |
| CN109745580A (en) * | 2019-02-28 | 2019-05-14 | 天津大学 | Anticoagulant peptides and the co-modified small-caliber artificial blood vessel and preparation method of cell adhesion polypeptide |
| CN209108208U (en) * | 2017-12-29 | 2019-07-16 | 上海纽脉医疗科技有限公司 | A kind of renewable heart valve and its preparation facilities and heart valve prosthesis |
| CN111420120A (en) * | 2020-05-28 | 2020-07-17 | 四川大学 | Biological valve with anticoagulation and anti-calcification functions and preparation method thereof |
| CN111514375A (en) * | 2020-05-28 | 2020-08-11 | 四川大学 | Anti-calcification biological valve material and preparation method thereof |
| CN111569152A (en) * | 2020-05-28 | 2020-08-25 | 四川大学 | Biological valve with anticoagulation and calcification resistance and preparation method thereof |
| CN111658824A (en) * | 2020-06-15 | 2020-09-15 | 四川大学 | Valve membrane material with synergistic anticoagulation and anti-calcification functions and preparation method thereof |
| CN113101412A (en) * | 2021-03-02 | 2021-07-13 | 四川大学华西医院 | Long-acting stable anticoagulation biological valve material and preparation method thereof |
| CN113425910A (en) * | 2021-07-30 | 2021-09-24 | 中南大学湘雅二医院 | Composite cross-linked biological valve and preparation method thereof |
-
2021
- 2021-10-22 CN CN202111231079.5A patent/CN113769169A/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2237229A1 (en) * | 1998-05-08 | 1999-11-08 | Derek Boughner | An improved bioprosthetic heart valve |
| CN107412865A (en) * | 2016-10-27 | 2017-12-01 | 浙江保尔曼生物科技有限公司 | The decellularization kidney biological support and preparation method with anticoagulant functions of high intensity |
| CN107441556A (en) * | 2017-07-05 | 2017-12-08 | 北京大清生物技术股份有限公司 | A kind of tissue mending material of polyaminoacid end-blocking and preparation method thereof |
| CN209108208U (en) * | 2017-12-29 | 2019-07-16 | 上海纽脉医疗科技有限公司 | A kind of renewable heart valve and its preparation facilities and heart valve prosthesis |
| CN108404219A (en) * | 2018-02-11 | 2018-08-17 | 华中科技大学 | A kind of small-caliber artificial blood vessel and preparation method thereof based on freezing casting technology |
| CN109745580A (en) * | 2019-02-28 | 2019-05-14 | 天津大学 | Anticoagulant peptides and the co-modified small-caliber artificial blood vessel and preparation method of cell adhesion polypeptide |
| CN111420120A (en) * | 2020-05-28 | 2020-07-17 | 四川大学 | Biological valve with anticoagulation and anti-calcification functions and preparation method thereof |
| CN111514375A (en) * | 2020-05-28 | 2020-08-11 | 四川大学 | Anti-calcification biological valve material and preparation method thereof |
| CN111569152A (en) * | 2020-05-28 | 2020-08-25 | 四川大学 | Biological valve with anticoagulation and calcification resistance and preparation method thereof |
| CN111658824A (en) * | 2020-06-15 | 2020-09-15 | 四川大学 | Valve membrane material with synergistic anticoagulation and anti-calcification functions and preparation method thereof |
| CN113101412A (en) * | 2021-03-02 | 2021-07-13 | 四川大学华西医院 | Long-acting stable anticoagulation biological valve material and preparation method thereof |
| CN113425910A (en) * | 2021-07-30 | 2021-09-24 | 中南大学湘雅二医院 | Composite cross-linked biological valve and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115645618A (en) * | 2021-11-17 | 2023-01-31 | 四川大学 | Method for preparing biological valve material by co-crosslinking and double-bond crosslinking and biological valve material |
| CN115645618B (en) * | 2021-11-17 | 2023-11-24 | 四川大学 | Method for preparing biological valve material by co-crosslinking and double bond crosslinking and biological valve material |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Electrospun photocrosslinkable hydrogel fibrous scaffolds for rapid in vivo vascularized skin flap regeneration | |
| Sheng et al. | Electrospun PCL/Gel-aligned scaffolds enhance the biomechanical strength in tendon repair | |
| KR20170140302A (en) | Dry animal-derived collagen fiber tissue material and manufacturing method thereof, and bioprosthetic insert | |
| Gao et al. | Comparative evaluation of decellularized porcine liver matrices crosslinked with different chemical and natural crosslinking agents | |
| US20210268151A1 (en) | Pre-Loadable Biological Heart Valve Capable of Rapid Rehydration and Preparation Method Thereof | |
| JP7448491B2 (en) | Method of preparing biological tissue for surgical transplantation | |
| EP3011981A1 (en) | A biomaterial scaffold for regenerating the oral mucosa | |
| CN111420120A (en) | Biological valve with anticoagulation and anti-calcification functions and preparation method thereof | |
| CN1775304A (en) | Method for preparing artificial biological valve with biological activity | |
| WO2022057841A1 (en) | Prosthetic heart valve and preparation method therefor | |
| CN113769169A (en) | Anticoagulation cell adhesion-promoting biological valve material and preparation method thereof | |
| US20230347016A1 (en) | Valve material with long-acting antithrombosis property and preparation method therefor | |
| Vasudev et al. | Effect of alternative crosslinking techniques on the enzymatic degradation of bovine pericardia and their calcification | |
| CN110812529A (en) | Injectable hydrogel and preparation method thereof | |
| CN109069263B (en) | Porcine cornea acellular method, acellular cornea and lamellar dry cornea using method | |
| WO2023060808A1 (en) | Composite hydrogel, preparation method therefor and application thereof | |
| CN111514375B (en) | Anti-calcification biological valve material and preparation method thereof | |
| Bakhtiar et al. | Fabrication and characterization of a novel injectable human amniotic membrane hydrogel for dentin-pulp complex regeneration | |
| EP2286824B1 (en) | Non-covalent crosslinking agent for collagen | |
| CN114949347B (en) | Modified crosslinked biological valve and preparation method and application thereof | |
| RU2012126633A (en) | METHOD FOR SCREENING AN AGENT SUITABLE FOR TREATING A DRY EYE SYNDROME AND / OR CORNEAL AND CONJUNCTIVES, PHARMACEUTICAL COMPOSITION OBTAINED WITH THIS METHOD | |
| CN109550082A (en) | A kind of preparation method of acellular matrix gel | |
| CN111359020B (en) | Soft tissue repair material and preparation method and application thereof | |
| CN110339401A (en) | A kind of orthopaedics compound bio amnion preparation method | |
| CN109010927A (en) | It is a kind of can slow releasing bioactivity factor de- cell bovine pericardium matrix preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211210 |